Abstract
Cancer chemotherapy is not free of undesirable side effects. With respect to the cardiovascular system, cardiotoxicity is a well-described and potentially lethal side effect of certain chemotherapeutic agents, such as anthracyclines. However, in the last few years, several clinical studies have taken into account the fact that some non-anthracycline chemotherapy treated-patients also have a significantly increased risk of cardiovascular events. The exact mechanism of this toxicity is not known, and several possibilities, including vascular autonomic neuropathy and vascular damage, have been proposed. The aim of the present review was to collate information on the clinical and experimental evidence regarding vascular toxicity for each of the different groups of chemotherapeutic agents. The mechanisms proposed to underlie this toxicity are also discussed.
Keywords: Vascular toxicity, chemotherapeutic drugs
Current Vascular Pharmacology
Title: Vascular Toxicity of Chemotherapeutic Agents
Volume: 8 Issue: 5
Author(s): Visitacion Lopez-Miranda, Esperanza Herradon, Cristina Gonzalez and Ma Isabel Martin
Affiliation:
Keywords: Vascular toxicity, chemotherapeutic drugs
Abstract: Cancer chemotherapy is not free of undesirable side effects. With respect to the cardiovascular system, cardiotoxicity is a well-described and potentially lethal side effect of certain chemotherapeutic agents, such as anthracyclines. However, in the last few years, several clinical studies have taken into account the fact that some non-anthracycline chemotherapy treated-patients also have a significantly increased risk of cardiovascular events. The exact mechanism of this toxicity is not known, and several possibilities, including vascular autonomic neuropathy and vascular damage, have been proposed. The aim of the present review was to collate information on the clinical and experimental evidence regarding vascular toxicity for each of the different groups of chemotherapeutic agents. The mechanisms proposed to underlie this toxicity are also discussed.
Export Options
About this article
Cite this article as:
Lopez-Miranda Visitacion, Herradon Esperanza, Gonzalez Cristina and Isabel Martin Ma, Vascular Toxicity of Chemotherapeutic Agents, Current Vascular Pharmacology 2010; 8 (5) . https://dx.doi.org/10.2174/157016110792007012
DOI https://dx.doi.org/10.2174/157016110792007012 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Endoplasmic Reticulum Stress, Diabetes Mellitus, and Tissue Injury
Current Protein & Peptide Science Therapeutic Modulation of Cytokines in Chronic Infectious Diseases
Current Pharmaceutical Design HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets Withdrawal Notice: COVID-19: Outbreak to Global
Anti-Infective Agents Genes Involved in Hereditary Hearing Impairment
Current Genomics Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor
Current Drug Delivery Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus
Infectious Disorders - Drug Targets Editorial [Bioengineering and Clinical Perspectives in Diagnostic and Therapeutic Applications of Microbubbles (Executive Guest Editor: Theodore G. Papaioannou)]
Current Pharmaceutical Design Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Human Heart Failure: A Proteomics Perspective
Current Proteomics Outlook of Ferroptosis-Targeted Lipid Peroxidation in Cardiovascular Disease
Current Medicinal Chemistry MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences Chlorpyrifos with Age-Dependent Effects in Cardiac Tissue of Male Rats
Current Molecular Pharmacology Animal Models of Systemic Sclerosis
Current Pharmaceutical Design Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Animal Models and Methods of Myocardial Infarction Induction and the Role of Tissue Engineering in the Regeneration of Damaged Myocardium
Current Stem Cell Research & Therapy Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry